|

CSL300 Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: Clazakizumab

Pipeline

Phase 1: 1Phase 2/3: 1

Top Sponsors

CSL Behring2

Indications

Diabetes2
End Stage Kidney Disease (ESKD)1
Atherosclerotic Cardiovascular Disease in Patients With ESKD1
End Stage Kidney Disease1
Atherosclerotic Cardiovascular Disease1

Other1 trial

A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

Phase 1

Decatur, Alabama1 trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Nephrology of North Alabama

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.